4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease

Journal of Neuropathology and Experimental Neurology

Volumn 56, Issue 8, 1997, Pages 866-871

  Montine, K S ^a,c   Kim, P J ^a   Olson, S J ^d   Markesbery, W R ^b   Montine, T J ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; PYRROLE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOREACTIVITY; LIPID PEROXIDATION; MALE; NEUROPATHOLOGY; NEUROTOXICITY; PARKINSON DISEASE; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; VIRUS ENCEPHALITIS;

EID: 0030791446     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199708000-00004     Document Type: Article

References (52)

1. Blass JP. Pathophysiology of the Alzheimer's syndrome. Neurology 1993;43:S25-S38
2. Roses A. On the metabolism of apolipoprotein E and the Alzheimer diseases. Exp Neurol 1995;132:149-56
3. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Proc Natl Acad Sci 1995;92:4725-27
4. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-84
5. Ames BN, Shigenaga MK. Oxidants are a major contributor to aging. In: Franceschi C, Cristofalo VJ, Vijg J, eds. Aging and cellular defense mechanisms. New York, NY Acad Sci 1992:85-95
6. Stadtman ER. Protein oxidation and aging. Science 1992;257: 1220-24
7. Mecocci P, MacGarvey U, Kaufman AE, et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 1993;34:609-16
8. Smith CD, Carney JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc Natl Acad Sci 1991;88:10540-43
9. Subbarao KV, Richardson JS, Ang LC. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 1990;55:342-45
10. Peterson C, Goldman JE. Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci 1986;83:2758-62
11. Pappolla MA, Omar RA, Kim KS, Robakis NK. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am J Pathol 1992;140:621-28
12. Martins RN, Harper CG, Stokes GB, Masters CL. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 1986;46:1042-45
13. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994;36:747-51
14. Lovell M, Ehmann W, Butler S, Markesbery W. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995;45:1594-1601
15. Gsell W, Conrad R, Hickethier M, et al. Decreased catalase activity but unchanged Superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 1995;64:1216-23
16. Gotz ME, Freyberger A, Hauer E, et al. Susceptibility of brains from patients with Alzheimer's disease to oxygen-stimulated lipid peroxidation and differential scanning calorimetry. Dementia 1992;3:213-22
17. Furuta A, Price DL, Pardo CA, et al. Localization of Superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol 1995;146:357-67
18. Farber JL. Mechanisms of cell Injury. In: Craighead JE, ed. Pathology of environmental and occupational disease. Philadelphia, Mosby 1996:287-302
19. Montine TJ, Amarnath V, Martin ME, et al. E-4-Hydroxy-2-nonenal is cytotoxic and crosslinks cytoskeletal proteins in P19 neuroglial cultures. Am J Pathol 1996;148:89-93
20. Montine TJ, Huang DY, Valentine WM, et al. Crosslinking of apolipoprotein E by products of lipid peroxidation. J Neuropathol Exp Neurol 1996;55:202-10
21. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nature Genetics 1996;14:55-61
22. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128
23. Nadkarni DV, Sayre LM. Structural definition of early lysine and histidine adduction chemistry of 4-hydroxynonenal. Chem Res Toxicol 1995;8:284-91
24. Sayre LM, Sha W, Xu G, et al. Immunochemical evidence supporting 2-pentylpyrrole formation on proteins exposed to 4-hydroxy-2-nonenal. Chem Res Toxicol 1996;9:1194-1201
25. Sayre LM, Arora PK, Iyer RS, Salomon RG. Pyrrole formation from 4-hydroxynonenal and primary amines. Chem Res Toxicol 1993;6:19-22
26. Montine K, Olson S, Amarnath V, et al. Immunochemical detection of 4-hydroxynonenal adducts in Alzheimer's disease is associated with APOE4. Am J Pathol 1997;150:437-43
27. Graham DG, Amarnath V, Valentine WM, et al. Pathogenetic studies of hexane and carbon disulfide neurotoxicity. Critical Reviews in Toxicology 1995;25:91-112
28. Good PF, Werner P, Hsu A, et al. Evidence for neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996;149:21-28
29. Smith MA, Kutty RK, Richey PL, et al. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 1994;145:42-47
30. Smith MA, Perry G, Richey PL, et al. Oxidative damage in Alzheimer's. Nature 1996;382:120-21
31. Yan SD, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994;91:7787-91
32. Yan SD, Yan SF, Chen X, et al. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nature Medicine 1995;1:693-99
33. Sayre LM, Zelasko DA, Harris PLR, et al. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer disease. J Neurochem 1997;68:2092-97
34. Brun A, England B, Gustafson L. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiat 1994;57:416-18
35. Esiri MM, Hyman BT, Beyreuther K, Masters C. Ageing and dementia. In: Graham DI, Lantos PI, eds. Greenfield's neuropathology. London, Arnold 1997:153-234
36. Gibb WRG. Neuropathology of the substantia nigra. Eur Neurol 1991;31:48-59
37. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-1105
38. Lowe J, Lennox G, Leigh PN. Disorders of movement and system degenerations. In: Graham DI, Lantos PL, eds. Greenfield's neuropathology. London, Arnold 1997:281-366
39. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41(4):479-86
40. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ε 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43(8):1467-72
41. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of β-amyloid. New Eng J Med 1995;333:1242-47
42. Adamson DC, Wildemann B, Sasaki M, et al. Immunologic NO synthase: Elevation in severe AIDS dementia and induction by HIV-1 gp41. Science 1996;274:1917-21
43. Pace GW, Leaf CD. The role of oxidative stress in HIV disease. Free Radical Biology and Medicine 1995;19:523-28
44. Castellani R, Smith MA, Richey PL, et al. Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res 1995;696:268-71
45. Farrer LA, Abraham CR, Volicer L, et al. Allele ε 4 of apolipoprotein E shows a dose effect on age at onset of Pick's disease. Exp Neurol 1995;136(2):162-70
46. Pickering-Brown SM, Mann DMA, Bourke JP. Apolipoprotein E4 and Alzheimer's disease pathology in Lewy body disease and in other β-amyloid-forming diseases. Lancet 1994;343:1155
47. Arai H, Higuchi S, Muramatsu T, et al. Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease. Lancet 1994;344:1307
48. Benjamin R, Leake A, Edwardson JA, et al. Apolipoprotein E genes in Lewy body and Parkinson's disease. Lancet 1994;343:1565
49. Katzman R, Galasko D, Saitoh T, et al. Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Brain and Cognition 1995;28:259-65
50. Bowling AC, Beal MF. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sciences 1994;56:1151-71
51. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-95
52. Yoritaka A, Hattori N, Uchida K, et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 1996;93:2696-2701